© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 20, 2022
TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.
December 19, 2021
The social determinants of health disparities have expanded the definition of personalized medicine, Karen Winkfield, MD, PhD, said.
December 16, 2021
APVO436 appears to be safe and effective for the treatment of acute myeloid leukemia or myelodysplastic syndrome.
December 14, 2021
Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.
December 12, 2021
Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety.
December 11, 2021
Looking at frontline venetoclax based combinations shows promise for fit patients with CLL.